Pre-Meeting Categorical Seminars*

All Pre-Meeting Categorical Seminars take place on Saturday, June 22, 2019.

SNMMI's Annual Meeting offers full-day categorical seminars to provide you with a deeper level of understanding as you examine a single topic of clinical, scientific, or academic interest. 

Updates and Advances in Molecular Neuroimaging

Sponsored by the Brain Imaging Council

This categorical seminar aims not only as an update of new techniques but also as a reminder of the usefulness of proven techniques, including assessing cerebral glucose metabolism, assessing nigrostriatal integrity and neuroreceptor imaging applied to neurodegenerative and neuropsychiatric conditions. By the end of the seminar, you will have a comprehensive update on tracers and techniques, their validation, a deeper knowledge of the underlying neurological and neuropsychiatric conditions, as well as the state-of-the-art methods used to standardize visual and quantitative interpretation of the images.

Image Guided Decision Making and Therapy for Optimal Cardiovascular Patient Cares

Sponsored by the Cardiovascular Council and PET Center of Excellence

This full-day categorical seminar has seven 1-hour themes centered on the topics of: Coronary Artery Disease ([1] Chest pain and suspected or known CAD, [2] Chest pain and suspected microvascular disease), Congestive Heart Failure ([3 Ischemic LV dysfunction and revascularization, [4] Amyloidosis, [5] Sarcoidosis), [6] Infection (valve, device, LVAD) and [7] Arrhythmias. Multimodality imaging will be emphasized and include SPECT, PET, CT and CMR imaging.

Molecular Imaging of Autoimmunity and Immune Checkpoint Inhibition 

sponsored by the Center for Molecular Imaging Innovation and Translation, Radiopharmaceutical Sciences Council, and PET Center of Excellence

This categorical seminar will provide you with a summary of the approaches being developed to monitor autoimmune responses, including T-cell targeted and macrophage/monocyte imaging approaches, and challenges in the development of these approaches. The session will focus on how these novel approaches could enable the imaging community to contribute to the improvement of patient treatment outcomes with immune checkpoint inhibitors.

Theranostics: Regulatory Considerations for Product Development

Sponsored by the Clinical Trials Network and the U.S. Food and Drug Administration

This full day categorical seminar will describe clinical, nonclinical and CMC information needed for theranostics product development. Specifically, the workshop will discuss regulatory perspectives of products that combine an imaging modality with therapeutic radiopharmaceuticals.

The content will be specific to the needs of the community based on what FDA members in the Medical Imaging and other divisions are seeing in INDs, NDAs, aNDAs, and DMF applications filed with the agency and in other interactions with the community. Members of FDA will deliver the important information and answer questions.

Molecular Imaging of Inflammation and Infection: Today and Tomorrow

Sponsored by the General Clinical Nuclear Medicine Council

This categorical seminar will review the current status of molecular imaging of inflammation and infection as well as updates on new and evolving developments in the field. In addition to a review of currently available single photon and positron emitting radiopharmaceuticals, along with their indications, pitfalls and artifacts, this seminar will highlight the role of molecular imaging in fever of unknown origin, sarcoid, HIV associated infections, and tuberculosis. Molecular imaging of pediatric infections as well as recent advances in the development of new agents including infection specific radiopharmaceuticals and the renewed interest in radiolabeled antibiotics also will be reviewed.

Artificial Intelligence (AI) Methods and Applications in Radiology and Nuclear Medicine

Sponsored by the Physics, Instrumentation and Data Sciences Council and Academic Council

This categorical seminar aims to provide both a general introduction as well as in-depth elucidation of AI for medical imaging. We aim to provide both a foundational overview of the basic concepts and methods in AI, and how these methods are increasingly applied in imaging including anatomic radiology and nuclear medicine/molecular imaging. We will review state-of-the-art applications in several areas (e.g., image segmentation, image classification, predictive modeling, etc.). Various applications including oncologic as well as cardiovascular will be elaborated. We will also discuss current challenges, limitations, and ways forward.

The course is intended to provide the attendees with deeper understanding of emerging AI techniques and applications, and tools needed for translation of these methods to routine clinical imaging, with the potential to significantly improve diagnosis, prognosis and treatment response assessment, and to take a significant step towards realization of precision (personalized) medicine. We also aim to provide a venue for significant Q&A as well as panel discussions in this categorical.

Radiopharmaceuticals for Molecular Imaging of Mental Disorders

Sponsored by the Radiopharmaceutical Sciences Council and the National Institutes of Health/National Institute of Mental Health

This categorical session will review current and new biological targets and radiotracers available to study (patho)physiology in mental disorders. Special attention will be given to the radiotracers targeting neurotransmitter receptors, ion channels and enzymes in the brain. Application of these radiotracers as imaging biomarkers in preclinical and clinical research as well as in drug development will be discussed.

Thyroid Cancer Theranostics: The Evolving Role for Nuclear Medicine in Clinical Genomics Paradigm

Sponsored by the Therapy Center of Excellence and Correlative Imaging Council

This categorical seminar will provide an overview of theranostic concepts in thyroid cancer management, concentrating on the genomics of thyroid cancer and discussion of molecular testing. It will review the role of molecular testing in the differential diagnosis of thyroid nodules. The rationale and clinical role for RAI imaging and treatment will be discussed in the context of the theranostic value of genomics and molecular profiling, with special reference to I-124 PET/CT and dosimetry, as well as FDG PET/CT. Both pediatric and adult populations will be reviewed.

 

* Additional registration fees may apply. A Categorical seminar is included for Weekend Only Attendees. *Members who are also members of a Council or Center will receive a $20 discount when registering online for a Physician/Scientist Categorical.